The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer - and in particular B-cell malignancies - are aspects of the present invention.Radioimunokonjugat koji se vezuje za čovečji CD37, koji se sastoji oda) mišjeg monoklonskog antitela HH1b) helirajućeg linkera, ic) radionuklida, iz grupe koju sačinjavaju 177Lu, 212Pb, 225Ac, 227Th i 90Y.Prijava sadrži još 12 patentnih zahteva.